Clean Science & Technology Ltd

Clean Science & Technology Ltd

₹ 1,425 0.98%
13 Dec - close price
About

Incorporated in 2003, Clean Science and Technology Ltd is one of the leading chemical manufacturers globally. It manufactures functionally critical specialty chemicals such as Performance Chemicals (MEHQ, BHA, and AP), Pharmaceutical Intermediates (Guaiacol and DCC), and FMCG Chemicals (4-MAP and Anisole). [1]

Key Points

Product Portfolio[1]
Company has the largest capacity in the world for their flagship products.
Performance Chemicals
1. MEHQ No.1 in world.
Used as polymerization inhibitor in acrylic acids, acrylic esters, super absorbent polymers (diapers and sanitary pads),Pre-cursor for agrochemical industry.
2. BHA No.1 in world
Used as anti-oxidant in food and feed industry
3. AP No.1 in world
Used in infant food formulations, breakfast cereals and cosmetics
4. TBHQ No.2 in World
Stabilizer in oil industry
5. HALS No.1 in India
HALS 701 is used in water treatment
HALS 770 is used for UV stabilization in a variety of polymers
Pharma & agro Intermediates
1. Guaiacol : No.1 in India & No.2 in World
Pre-cursor to manufacture APIs for cough syrup
Key raw material to produce Vanillin
2. DCC (Dicyclohexyl Carbodiimide) No.1 in India & No.2 in World
Used as reagent in anti-retroviral
3. p-BQ (Para Benzoquinone) No.1 in India & No.2 in World
Intermediate in agrochemical industry
FMCG Chemicals
1. 4-MAP No.1 in world
Used in UV blocker in sunscreens
2. Anisole : No.1 in world
Precursor to perfumes, insect pheromones, pharmaceuticals
Majority of Anisole produced is used for captive consumption

  • Market Cap 15,145 Cr.
  • Current Price 1,425
  • High / Low 1,690 / 1,243
  • Stock P/E 58.8
  • Book Value 122
  • Dividend Yield 0.35 %
  • ROCE 29.6 %
  • ROE 22.0 %
  • Face Value 1.00

Pros

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 29.0%
  • Company has been maintaining a healthy dividend payout of 18.3%

Cons

  • Stock is trading at 11.7 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
153 181 205 234 248 237 217 188 181 195 228 224 238
84 105 121 143 150 129 112 112 106 108 133 129 148
Operating Profit 69 76 84 91 97 108 105 76 75 87 95 95 90
OPM % 45% 42% 41% 39% 39% 46% 48% 40% 41% 44% 42% 42% 38%
9 7 7 2 3 13 13 13 6 8 14 10 11
Interest 0 0 0 0 0 0 0 0 0 0 1 0 0
Depreciation 6 6 7 8 9 9 10 11 11 11 13 16 18
Profit before tax 71 78 84 85 92 112 108 79 69 83 95 89 83
Tax % 25% 25% 26% 26% 26% 25% 25% 25% 25% 25% 26% 26% 29%
54 58 62 63 68 84 81 59 52 63 70 66 59
EPS in Rs 5.04 5.46 5.87 5.92 6.40 7.89 7.58 5.55 4.91 5.89 6.61 6.20 5.53
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
241 393 419 512 685 936 791 884
167 257 234 253 385 533 459 519
Operating Profit 74 137 186 260 300 403 332 365
OPM % 31% 35% 44% 51% 44% 43% 42% 41%
5 11 11 25 30 30 41 43
Interest 1 0 0 0 0 1 1 1
Depreciation 8 11 14 17 25 36 46 57
Profit before tax 70 137 182 267 305 396 326 350
Tax % 30% 28% 23% 26% 25% 25% 25%
49 98 140 198 228 295 244 258
EPS in Rs 345.41 689.84 1,051.67 18.68 21.51 27.78 22.97 24.23
Dividend Payout % 12% 15% 2% 134% 15% 18% 22%
Compounded Sales Growth
10 Years: %
5 Years: 15%
3 Years: 16%
TTM: 7%
Compounded Profit Growth
10 Years: %
5 Years: 20%
3 Years: 7%
TTM: -6%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -17%
1 Year: -6%
Return on Equity
10 Years: %
5 Years: 33%
3 Years: 29%
Last Year: 22%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 1 1 1 11 11 11 11 11
Reserves 186 271 341 529 758 999 1,193 1,287
1 3 3 0 0 2 2 2
48 53 85 120 156 140 191 201
Total Liabilities 236 327 430 660 925 1,152 1,396 1,501
102 127 166 186 296 460 636 687
CWIP 2 4 3 55 44 20 57 30
Investments 18 75 133 232 191 353 339 359
114 121 128 187 394 318 363 425
Total Assets 236 327 430 660 925 1,152 1,396 1,501

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
45 85 160 193 127 279 237
-17 -94 -105 -187 -79 -270 -186
-5 -11 -55 -6 -0 -55 -53
Net Cash Flow 23 -20 -0 0 49 -45 -2

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 60 55 61 53 82 57 76
Inventory Days 93 79 98 156 143 122 163
Days Payable 85 48 101 180 166 90 143
Cash Conversion Cycle 69 87 58 29 59 89 96
Working Capital Days 60 64 35 32 90 68 86
ROCE % 59% 59% 61% 47% 44% 30%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
78.51% 78.51% 78.51% 78.50% 78.50% 78.50% 74.98% 74.98% 74.98% 74.98% 74.98% 74.97%
5.05% 5.18% 4.43% 4.43% 3.99% 3.99% 5.84% 6.01% 5.92% 5.88% 6.05% 5.83%
4.28% 4.02% 4.51% 4.48% 4.65% 4.76% 6.41% 5.23% 5.13% 5.04% 4.55% 4.77%
12.16% 12.29% 12.55% 12.58% 12.86% 12.74% 12.78% 13.79% 13.98% 14.11% 14.42% 14.43%
No. of Shareholders 2,42,6422,63,5932,70,4462,70,6162,75,1022,70,8232,66,9712,85,2592,78,6532,79,3952,73,8412,54,629

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls